Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
Amitriptyline |
EINECS | 200-041-6 |
CAS No. | 50-48-6 | Density | 1.076 g/cm3 |
PSA | 3.24000 | LogP | 4.97060 |
Solubility | water: 9.7 mg/mL | Melting Point |
196-197 °C |
Formula | C20H23N | Boiling Point | 398.2 °C at 760 mmHg |
Molecular Weight | 277.409 | Flash Point | 174 °C |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | R36/37/38 | |
Molecular Structure | Hazard Symbols | Xi | |
Synonyms |
5H-Dibenzo[a,d]cycloheptene-D5,g-propylamine, 10,11-dihydro-N,N-dimethyl- (6CI,8CI);5-(g-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene;Adepress;Amitriptylin;Damilen;MK 230;N 750;Proheptadiene;Seroten;Triptanol;Triptisol; |
Article Data | 40 |
Conditions | Yield |
---|---|
With sodium tetrahydroborate In water at 50 - 60℃; chemoselective reaction; | 98% |
Conditions | Yield |
---|---|
With formic acid; triethylamine In water; tert-butyl alcohol at 100℃; for 14h; | 89% |
Conditions | Yield |
---|---|
In ethanol at 200℃; under 82508.3 Torr; for 0.01h; Solvent; Temperature; Flow reactor; | 78% |
carbon dioxide
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Amitriptyline
Conditions | Yield |
---|---|
With diphenylsilane; [1,3-bis(2,4,6-trimethylphenyl)imidazol]-2-ylidene In N,N-dimethyl-formamide at 50℃; under 760.051 Torr; chemoselective reaction; | 63% |
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 24h; Autoclave; Inert atmosphere; | 81 %Chromat. |
Amitriptyline
Conditions | Yield |
---|---|
With trifluorormethanesulfonic acid In dichloromethane at 0℃; for 0.166667h; Friedel-Crafts Alkylation; regioselective reaction; | 56% |
Conditions | Yield |
---|---|
Multi-step reaction with 3 steps 1: n-butyllithium; carbon dioxide / tetrahydrofuran; hexane / -50 - 20 °C / 3878.71 Torr / Flow reactor 2: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor 3: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor View Scheme | |
Multi-step reaction with 3 steps 1: n-butyllithium; carbon dioxide / tetrahydrofuran; hexane / -50 - 20 °C / Flow reactor 2: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor 3: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor View Scheme |
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: methanol / tetrahydrofuran; toluene / 20 °C / Flow reactor 2: ethanol / 0.01 h / 200 °C / 82508.3 Torr / Flow reactor View Scheme |
formic acid
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
Amitriptyline
Conditions | Yield |
---|---|
With platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex; 1,3-bis-(diphenylphosphino)propane; phenylsilane In dibutyl ether at 60℃; for 18h; Schlenk technique; Inert atmosphere; | 94 %Chromat. |
Amitriptyline
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: ethanol; water / 2 h / 50 °C 2: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C View Scheme |
Conditions | Yield |
---|---|
Multi-step reaction with 6 steps 1: bis-triphenylphosphine-palladium(II) chloride; triethylamine; copper(l) iodide / acetonitrile / 22 h / 0 - 20 °C 2: hydrogen; palladium 10% on activated carbon / ethyl acetate / 6 h / 20 °C 3: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C 4: triethylamine / dichloromethane / 2.5 h / 0 °C 5: ethanol; water / 2 h / 50 °C 6: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C View Scheme |
Molecular Structure:
Molecular Formula: C20H23N
Molecular Weight: 277.4033
IUPAC Name: (3S,4R)-3-(1,3-Benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
Synonyms of Amitriptyline (CAS NO.50-48-6): 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene ; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(sup 5),gamma-propylamine ; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin ; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine ; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene ; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene ; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene ; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene ; 5H-Dibenzo(a,d)cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N,N-dimethyl- ; Adepress ; Adepril ; Amitriptilina ; Amitriptilina [INN-Spanish] ; Amitriptilina [Italian] ; Amitriptylin ; Amitriptylin [German] ; Amitriptylinum ; Amitriptylinum [INN-Latin] ; Amytriptylin ; BRN 2217885 ; CCRIS 9174 ; Damilen ; Damitriptyline ; EINECS 200-041-6 ; Elavil ; Flavyl ; Lantron ; MK 230 ; N 750 ; Proheptadiene ; Redomex ; Ro 4-1575 ; Seroten ; Triptanol ; Triptilin ; Triptisol ; Tryptanol ; UNII-1806D8D52K ; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- ; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-
CAS NO: 50-48-6
Classification Code: Adrenergic Agents ; Adrenergic uptake inhibitors ; Analgesics ; Analgesics, Non-Narcotic ; Antidepressive Agents ; Antidepressive agents, tricyclic ; Antihistaminic ; Central Nervous System Agents ; Drug / Therapeutic Agent ; Human Data ; Neurotransmitter Agents ; Neurotransmitter Uptake Inhibitors ; Peripheral Nervous System Agents ; Psychotropic Drugs ; Reproductive Effect ; Sensory System Agents
Melting point: 196-197°C
Index of Refraction: 1.628
Molar Refractivity: 91.52 cm3
Molar Volume: 257.7 cm3
Surface Tension: 47 dyne/cm
Density: 1.076 g/cm3
Flash Point: 174 °C
Enthalpy of Vaporization: 64.88 kJ/mol
Boiling Point: 398.2 °C at 760 mmHg
Vapour Pressure: 1.5E-06 mmHg at 25°C
Amitriptyline (CAS NO.50-48-6) is recommended for the treatment of mental depression, with improvement in mood seen in 2 to 3 weeks after the start of medication. It is now used in the United States and United Kingdom to prevent migraines only in very small doses. It is also used as sleeping aids in small doses of usually 25 mg, and for diabetic retinopathy.
The synthesis of Amitriptyline (CAS NO.50-48-6) starts from the key intermediate dibenzo-suberone (manufactured from phthalic anhydride) and can proceed by two pathways (Fig. 1). Treatment of dibenzosuberone with cyclopropyl Grignard gives the tertiary alcohol after hydrolysis. Reaction of the alcohol with hydrochloric acid proceeds with rearrangement and opening of the strained cyclopropane to give a chloride. Reaction and displacement of the chlorine atom with dimethylamine forms amitriptyline. Alternatively, dibenzosuberone can be reacted with dimethylaminopropyl Grignard to form an alcohol, which upon dehydration forms amitriptyline.
FIGURE 1 Manufacture of amitriptyline.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
child | TDLo | oral | 4500ug/kg (4.5mg/kg) | BEHAVIORAL: SLEEP | British Medical Journal. Vol. 3, Pg. 663, 1967. |
dog | LDLo | subcutaneous | 50mg/kg (50mg/kg) | PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Pharmacologist. Vol. 11, Pg. 283, 1969. |
guinea pig | LDLo | intravenous | 35mg/kg (35mg/kg) | Drugs of the Future. Vol. 8, Pg. 949, 1983. | |
human | TDLo | oral | 2mg/kg/3D-I (2mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS | British Journal of Clinical Pharmacology. Vol. 49, Pg. 118, 2000. |
human | TDLo | oral | 14mg/kg (14mg/kg) | CARDIAC: OTHER CHANGES | Proceedings of the European Society for the Study of Drug Toxicity. Vol. 6, Pg. 171, 1965. |
infant | TDLo | oral | 50mg/kg (50mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: CHANGE IN RATE BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | American Journal of Diseases of Children. Vol. 130, Pg. 507, 1976. |
man | LDLo | oral | 29mg/kg (29mg/kg) | Human & Experimental Toxicology. Vol. 9, Pg. 257, 1990. | |
man | TDLo | oral | 1564mg/kg/2Y- (1564mg/kg) | PERIPHERAL NERVE AND SENSATION: PARESTHESIS BEHAVIORAL: ATAXIA BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Italian Journal of Neurological Sciences. Vol. 9, Pg. 89, 1988. |
man | TDLo | unreported | 45mg/kg/21D (45mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) CARDIAC: CHANGE IN RATE | Lancet. Vol. 2, Pg. 1202, 1972. |
mouse | LD50 | intraperitoneal | 48400ug/kg (48.4mg/kg) | Farmakologiya i Toksikologiya Vol. 53(4), Pg. 19, 1990. | |
mouse | LD50 | intravenous | 16mg/kg (16mg/kg) | BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Journal of Medicinal Chemistry. Vol. 17, Pg. 65, 1974. |
mouse | LD50 | oral | 99mg/kg (99mg/kg) | Doklady Akademii Nauk SSSR. Proceedings of the Academy of Sciences of the USSR. For English translation, see DBIOAM and DKBSAS. Vol. 335, Pg. 388, 1994. | |
mouse | LD50 | subcutaneous | 100mg/kg (100mg/kg) | United States Patent Document. Vol. #4605673, | |
mouse | LD50 | unreported | 80mg/kg (80mg/kg) | AUTONOMIC NERVOUS SYSTEM: "SMOOTH MUSCLE RELAXANT (MECHANISM UNDEFINED, SPASMOLYTIC)" | Journal of Medicinal Chemistry. Vol. 10, Pg. 418, 1967. |
rabbit | LD50 | intraperitoneal | 58700ug/kg (58.7mg/kg) | LUNGS, THORAX, OR RESPIRATION: CYANOSIS | Journal of Toxicology, Clinical Toxicology. Vol. 19, Pg. 321, 1982. |
rabbit | LD50 | intravenous | 8600ug/kg (8.6mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 863, 1965. | |
rat | LD50 | intraperitoneal | 72mg/kg (72mg/kg) | Polish Journal of Pharmacology and Pharmacy. Vol. 27, Pg. 503, 1975. | |
rat | LD50 | oral | 320mg/kg (320mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS BEHAVIORAL: ATAXIA | Arzneimittel-Forschung. Drug Research. Vol. 15, Pg. 863, 1965. |
women | TDLo | intramuscular | 240ug/kg/36H- (0.24mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Lancet. Vol. 1, Pg. 390, 1968. |
women | TDLo | oral | 13500ug/kg/3D (13.5mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: EXCITEMENT | Lancet. Vol. 1, Pg. 390, 1968. |
women | TDLo | oral | 16800ug/kg/2W (16.8mg/kg) | PERIPHERAL NERVE AND SENSATION: PARESTHESIS BEHAVIORAL: HEADACHE | Lancet. Vol. 1, Pg. 426, 1968. |
women | TDLo | oral | 18500ug/kg (18.5mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 35, Pg. 795, 1993. |
women | TDLo | oral | 60mg/kg (60mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: CHANGE IN RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION | Journal of Toxicology, Clinical Toxicology. Vol. 19, Pg. 67, 1982. |
women | TDLo | oral | 84mg/kg (84mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE | Japanese Journal of Toxicology. Vol. 5, Pg. 69, 1992. |
Human poison by an unspecified route. Poison experimentally by ingestion, intraperitoneal, subcutaneous, intramuscular, and intravenous routes. Human systemic effects by ingestion and intramuscular routes: changes in sleep, headache, paresthesia, convulsions, excitement, somnolence, muscle contractions, change in heart rate, and other cardiac changes. An experimental teratogen. Other experimental reproductive effects. An antidepressant. When heated to decomposition it emits toxic fumes of NOx.
Common side effects of using amitriptyline are mostly due to its anticholinergic activity, including: weight gain, dry mouth, loss of appetite, drowsiness, muscle stiffness, nausea, constipation, nervousness, dizziness, blurred vision, urinary retention and insomnia. Some rare side effects include tinnitus, hypotension, mania, psychosis, heart block, arrhythmias, lip and mouth ulcers, extrapyramidal symptoms, depression, and hepatic toxicity.